SUBSCRIBE
SUBSCRIBE
News   Drug Development

Biogen Idec, Inc. (Massachusetts), Elan Corporation PLC Shares Fall on FDA Concerns

July 31, 2007 | 
1 min read
NEW YORK - Shares of biotechnology companies Biogen Idec Inc. and Elan Corp. fell Monday on concerns a Food and Drug Administration panel may recommend against approving Tysabri as a Crohn's disease treatment.
Clinical research Postmarket research
Food and Drug Administration (FDA) Biogen
MORE ON THIS TOPIC
businessman Climbing mountain. Symbol of success, career, leadership and goal
Immuno-oncology
Four Therapies Hanging On in Troubled TIGIT Space
July 7, 2025
 · 
9 min read
 · 
Tristan Manalac
vector illustration arrows miss the target board, concept of lost in focus, failure, fail, mistake
Immunology and inflammation
Late-Stage Stumble for Cosentyx Sets Novartis Back in Autoimmune Condition
July 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Painful female periods concept. Vector flat character illustration. Woman standing and suffering menstrual abdominal pain isolated on pink background. Design for health care.
Women’s Health
Organon’s Endometriosis Drug Discontinued After Failing To Improve Pain
July 2, 2025
 · 
1 min read
 · 
Annalee Armstrong
IN PARTNERSHIP WITH IQVIA
Understanding the FDA’s AI Guidance in Pharmacovigilance
July 1, 2025
 · 
1 min read
 · 
Lori Ellis